Mutation profiling and microsatellite instability in stage II and III colon cancer: An assessment of their prognostic and oxaliplatin predictive value

Clinical Cancer Research

Volumn 18, Issue 23, 2012, Pages 6531-6541

  Gavin, Patrick G ^a   Colangelo, Linda H ^a   Fumagalli, Debora ^a   Tanaka, Noriko ^a   Remillard, Matthew Y ^a   Yothers, Greg ^a   Kim, Chungyeul ^a   Taniyama, Yusuke ^a   Kim, Seung Il ^a   Choi, Hyun Joo ^a   Blackmon, Nicole L ^a   Lipchik, Corey ^a   Petrelli, Nicholas J ^a,c   O'Connell, Michael J ^a   Wolmark, Norman ^a,b   Paik, Soonmyung ^a   Pogue Geile, Kay L ^a  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b ALLEGHENY GENERAL HOSPITAL   (United States)

^c HELEN F GRAHAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; K RAS PROTEIN; OXALIPLATIN; SCATTER FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; BRAF GENE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COLON CANCER; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENE EXPRESSION PROFILING; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MET GENE; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; ONCOGENE K RAS; ONCOGENE N RAS; OVERALL SURVIVAL; PIK3CA GENE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; TUMOR GENE;

ANTINEOPLASTIC AGENTS; COLONIC NEOPLASMS; DNA MISMATCH REPAIR; HUMANS; MICROSATELLITE INSTABILITY; MUTATION; MUTATION RATE; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; TREATMENT OUTCOME;

EID: 84870339415     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0605     Document Type: Article

References (46)

1. Ogino S, Nosho K, Kirkner GJ, Shima K, Irahara N, Kure S, et al. PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol 2009;27:1477-84.
2. Fariña Sarasqueta A, Zeestraten E, van Wezel T, van Lijnschoten G, van Eijk R, Dekker J, et al. PIK3CA kinase domain mutation identifies a subgroup of stage III colon cancer patients with poor prognosis. Cell Oncol 2001;34:523-31.
3. Kato S, Iida S, Higuchi T, IshikawaT, Takagi Y, Yasuno M, et al. PIK3CA mutation is predictive of poor survival in patients with colorectal cancer. Int J Cancer 2007;121:1771-8. (Pubitemid 47417296)
4. Samowitz WS, Sweeney C, Herrick J, Albertsen H, Levin TR, Murtaugh MA, et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 2005;65:6063-9.
5. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009;58: 90-6.
6. Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010;28:466-74.
7. Fariña-Sarasqueta A, van Lijnschoten G, Moerland E, Creemers G-J, Lemmens VEPP, Rutten HJT, et al. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol 2010;21:2396-402.
8. Ogino S, Shima K, Meyerhardt JA, McCleary NJ, Ng K, Hollis D, et al. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from Intergroup Trial CALGB 89803. Clin Cancer Res 2012;18:890-900.
9. Saridaki Z, Papadatos-Pastos D, Tzardi M, Mavroudis D, Bairaktari E, Arvanity H, et al. BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients' outcome. Br J Cancer 2010;102:1762-8.
10. Barault L, Charon-Barra C, Jooste V, de la Vega MF, Martin L, Roignot P, et al. Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res 2008;68:8541-6.
11. French AJ, Sargent DJ, Burgart LJ, Foster NR, Kabat BF, Goldberg R, et al. Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res 2008;14: 3408-15.
12. Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, et al. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 2001;85:692-6. (Pubitemid 32929467)
13. Conlin A, Smith G, Carey FA, Wolf CR, Steele RJC. The prognostic significance of K-ras, p53, and APCmutations in colorectal carcinoma. Gut 2005;54:1283-6. (Pubitemid 41192491)
14. Lièvre A, Bachet J-B, Boige V, Cayre A, Le Corre D, Buc E, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374-9. (Pubitemid 351171687)
15. Zauber NP, Wang C, Lee PS, Redondo TC, Bishop DT, Goel A. Ki-ras gene mutations, LOH of the APC and DCC genes, and microsatellite instability in primary colorectal carcinoma are not associated with micrometastases in pericolonic lymph nodes or with patients' survival. J Clin Pathol 2004;57:938-42. (Pubitemid 39208244)
16. Hutchins G, Southward K, Handley K, Magill L, Beaumont C, Stahlschmidt J, et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol 2001;29:1261-70.
17. Fumagalli D, Gavin PG, Taniyama Y, Kim SI, Choi HJ, Paik S, et al. A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes. BMC Cancer 2010;10:101.
18. Kuebler JP, Wieand HS, O'Connell MJ, Smith RE, Colangelo LH, Yothers G, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007;25:2198-204. (Pubitemid 46954643)
19. Yothers G, O'Connell MJ, Allegra CJ, Kuebler JP, Colangelo LH, Petrelli NJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 2011;29:3768-74.
20. Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Petrelli NJ, Colangelo LH, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP Protocol C-08. J Clin Oncol 2011;29:11-6.
21. Forbes SA, Bhamra G, Bamford S, Dawson E, Kok C, Clements J, et al. The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum Genet 2008;Chapter 10:Unit 10.11.
22. Lambrechts D, De Roock W, Prenen H, De Schutter J, Jacobs B, Biesmans B, et al. The role of KRAS, BRAF, NRAS, and PIK3CA mutations as markers of resistance to cetuximab in chemorefractory metastatic colorectal cancer. J Clin Oncol (Meeting Abstracts) 27:15s, 2009 (suppl; abstr 4020).
23. Simi L, Pratesi N, Vignoli M, Sestini R, Cianchi F, Valanzano R, et al. High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. Am J Clin Pathol 2008;130:247-53.
24. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy- refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010;11:753-62.
25. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006;38:787-93. (Pubitemid 43980599)
26. Rozek LS, Herron CM, Greenson JK, Moreno V, Capella G, Rennert G, et al. Smoking, gender, and ethnicity predict somatic BRAF mutations in colorectal cancer. Cancer Epidemiol Biomarkers Prev 2010;19: 838-43.
27. Samowitz WS, Albertsen H, Herrick J, Levin TR, Sweeney C, Murtaugh MA, et al. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology 2005;129:837-45. (Pubitemid 41242676)
28. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002;418:934. (Pubitemid 34976022)
29. Elsaleh H, Cserni G, Iacopetta B. Extent of nodal involvement in stage III colorectal carcinoma: relationship to clinicopathologic variables and genetic alterations. Dis Colon Rectum 2002;45:1218-22.
30. Basu P, Chandna P, Bamezai RNK, Siddiqi M, Saranath D, Lear A, et al. Mass ARRAY spectrometry is more sensitive than pretect HPV-proofer and consensus PCR for type-specific detection of high-risk oncogenic human papillomavirus genotypes in cervical cancer. J Clin Microbiol 2011;49:3537-44.
31. Querings S, Altmüller J, Ansén S, Zander T, Seidel D, Gabler F, et al. Benchmarking of mutation diagnostics in clinical lung cancer specimens. PLoS One 2011;6:e19601.
32. Li WQ, Kawakami K, Ruszkiewicz A, Bennett G, Moore J, Iacopetta B. BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status. Mol Cancer 2006;5:2.
33. André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-51. (Pubitemid 38702845)
34. André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009;27:3109-16.
35. Ng K, Schrag D. Microsatellite instability and adjuvant fluorouracil chemotherapy: a mismatch? J Clin Oncol 2010;28:3207-10.
36. Loddenkemper C, Nagorsen D, Zeitz M. Foxp3 and microsatellite stability phenotype in colorectal cancer. Gut 2008;57:725-6. (Pubitemid 351716960)
37. Yuen ST, Davies H, Chan TL, Ho JW, Bignell GR, Cox C, et al. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res 2002;62:6451-5. (Pubitemid 35364105)
38. Barault L, Veyrie N, Jooste V, Lecorre D, Chapusot C, Ferraz J-M, et al. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer 2008;122:2255-9. (Pubitemid 351542328)
39. Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM, et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 2009;27:5931-7.
40. Liao X, Morikawa T, Lochhead P, Imamura Y, Kuchiba A, Yamauchi M, et al. Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin Cancer Res 2012;18:2257-68.
41. Popovici V, Budinska E, Tejpar S, Weinrich S, Estrella H, Hodgson G, et al. Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer. J Clin Oncol 2011;30:1288-95.
42. Drescher K, Sharma P, Watson P, Gatalica Z, Thibodeau S, Lynch H. Lymphocyte recruitment into the tumor site is altered in patients with MSI-H colon cancer. Fam Cancer 2009;8: 231-9.
43. Nosho K, Baba Y, Tanaka N, Shima K, Hayashi M, Meyerhardt JA, et al. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol 2010;222:350-66.
44. Mlecnik B, Bindea G, Pages F, Galon J. Tumor immunosurveillance in human cancers. Cancer Metastasis Rev 2011;30:5-12.
45. Foulds KE, Rotte MJ, Seder RA. IL-10 is required for optimal CD8 T cell memory following listeria monocytogenes infection. J Immunol 2006;177:2565-74. (Pubitemid 44201015)
46. Flaherty KT, Hodi FS, Bastian BC. Mutation-driven drug development in melanoma. Curr Opin Oncol 2010;22:178-3.